Opthea’s (OPT) Underperform Rating Reaffirmed at Jefferies Financial Group

Posted by Stephan Jacobs on Mar 25th, 2025

Opthea (NASDAQ:OPT – Get Free Report)‘s stock had its “underperform” rating reissued by equities research analysts at Jefferies Financial Group in a research report issued on Tuesday,Benzinga reports. They currently have a $1.00 target price on the stock. Jefferies Financial Group’s price objective suggests a potential downside of 70.67% from the company’s previous close.

Several other research analysts have also commented on OPT. Canaccord Genuity Group upgraded shares of Opthea to a “strong-buy” rating in a report on Tuesday, December 17th. Oppenheimer lowered shares of Opthea from an “outperform” rating to a “market perform” rating in a report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Opthea in a research report on Friday, February 28th.

Read Our Latest Stock Analysis on Opthea

Opthea Price Performance

Shares of Opthea stock opened at $3.41 on Tuesday. The company’s fifty day simple moving average is $4.43 and its two-hundred day simple moving average is $4.07. Opthea has a 12-month low of $1.79 and a 12-month high of $6.30.

Institutional Investors Weigh In On Opthea

A number of institutional investors and hedge funds have recently bought and sold shares of OPT. Citadel Advisors LLC purchased a new stake in Opthea in the 4th quarter worth $79,000. Hsbc Holdings PLC purchased a new stake in shares of Opthea during the 4th quarter worth approximately $556,000. OLD Mission Capital LLC bought a new position in shares of Opthea during the 4th quarter valued at approximately $42,000. ABC Arbitrage SA purchased a new position in shares of Opthea in the fourth quarter valued at $40,000. Finally, Twin Lakes Capital Management LLC bought a new stake in shares of Opthea in the 3rd quarter worth about $81,000. 55.95% of the stock is owned by institutional investors.

About Opthea

(Get Free Report)

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.